AlloVir: Clinical Trials

12 trials sponsored by AlloVir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 terminated, 2 withdrawn. 6 Phase 1, 5 Phase 2, 4 Phase 3, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 16Completed 2, Terminated 2, Withdrawn 2
Phase 25Completed 3, Terminated 2
Phase 34Terminated 3, Completed 1
Not applicable1Completed 1

Follow AlloVir: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Posoleucel, Placebo - Adenovirus Infection
Phase 3TerminatedAlloVir572022-04-262024-05-08
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Posoleucel (ALVR105), Placebo - Adenovirus Infection, BK Virus Infection
Phase 2 / Phase 3TerminatedAlloVir4512022-03-242024-05-16
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
ALVR106, Placebo - Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection
Phase 1 / Phase 2TerminatedAlloVir172022-03-212024-06-06
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel) - BK Virus Nephropathy, BK Virus Infection
Phase 2CompletedAlloVir612021-03-222024-05-16
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Posoleucel (ALVR105), Placebo - BK Virus Infection, Hemorrhagic Cystitis
Phase 3TerminatedAlloVir972021-03-182024-05-14
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Posoleucel (ALVR105) - Adenovirus Infection, BK Virus Infection
Phase 2 / Phase 3CompletedAlloVir262021-01-152024-05-09
Anti-SARS Cov-2 T Cell Infusions for COVID 19
Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs) - SARS-CoV 2, Viral Infection
Phase 1TerminatedBaylor College of Medicine42020-11-042022-12-19
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Viralym-B - BK Virus Infection
Phase 1WithdrawnAlloVir2018-03-012018-04-09
Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
Viralym-A - Adenovirus Infection
Phase 1WithdrawnAlloVir2017-12-072018-07-23
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Viralym-C - CMV Infections
Phase 1CompletedAlloVir102015-09-012018-12-26
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Multivirus Specific T cells - Infection
Not applicableCompletedAlloVir822014-06-012021-07-20
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3 - Viral Infection
Phase 1 / Phase 2CompletedAlloVir212012-09-012019-05-30

Conditions studied

Adenoviridae Infections (6)  ·  Cytomegalovirus Infections (4)  ·  Epstein-Barr Virus Infections (4)  ·  Virus Diseases (4)  ·  Infections (2)  ·  COVID-19 (1)  ·  Cystitis, Hemorrhagic (1)  ·  Paramyxoviridae Infections (1)  ·  Respiratory Tract Infections (1)

Interventions

Cell Count (1)  ·  Maximum Tolerated Dose (1)

Countries

United States (12)  ·  Italy (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  France (2)  ·  South Korea (2)  ·  Sweden (2)  ·  Australia (1)  ·  Belgium (1)  ·  Turkey (Türkiye) (1)

Top investigators

Bilal Omer, MD (3)  ·  Swati Naik, MD (3)  ·  Carlos A Ramos, MD (1)  ·  Helen Heslop, MD (1)  ·  Premal Lulla (1)

Results publications

PMID 38597860, PMID 24964991, PMID 36373249, PMID 36628536, PMID 37323051, PMID 38593233, PMID 39382091